Gail Eckhardt

2.1k total citations · 1 hit paper
20 papers, 1.6k citations indexed

About

Gail Eckhardt is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Gail Eckhardt has authored 20 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 8 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in Gail Eckhardt's work include Cancer Research and Treatments (3 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Cancer, Hypoxia, and Metabolism (2 papers). Gail Eckhardt is often cited by papers focused on Cancer Research and Treatments (3 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Cancer, Hypoxia, and Metabolism (2 papers). Gail Eckhardt collaborates with scholars based in United States, United Kingdom and Netherlands. Gail Eckhardt's co-authors include Razelle Kurzrock, Michael S. Gordon, G I Rodriguez, Stuart Kaye, A.G. Robertson, David H. Kirn, Daniel D. Von Hoff, Carla Heise, Sabine Eckhardt and Ian Ganly and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Gail Eckhardt

19 papers receiving 1.6k citations

Hit Papers

Safety, pharmacokinetic, pharmacodynamic, and efficacy da... 2012 2026 2016 2021 2012 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
    2012 424 citations Jeffrey R. Infante, Leslie A. Fecher et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gail Eckhardt United States 12 900 850 319 273 232 20 1.6k
Mark L. Levitt United States 16 1.1k 1.2× 799 0.9× 176 0.6× 349 1.3× 216 0.9× 43 1.9k
Ying C. Henderson United States 25 1.0k 1.1× 1.3k 1.5× 337 1.1× 509 1.9× 126 0.5× 39 2.4k
Jack A. Roth United States 17 906 1.0× 1.1k 1.3× 725 2.3× 200 0.7× 213 0.9× 28 1.9k
Dahmane Oukrif United Kingdom 18 780 0.9× 671 0.8× 228 0.7× 434 1.6× 455 2.0× 36 1.8k
Richard K. Rosenberg United States 9 853 0.9× 792 0.9× 207 0.6× 340 1.2× 64 0.3× 11 1.4k
Charanjit Sandhu Canada 11 1.7k 1.9× 1.7k 2.0× 148 0.5× 337 1.2× 137 0.6× 11 2.4k
Adam D. Steg United States 20 852 0.9× 1.2k 1.4× 221 0.7× 431 1.6× 123 0.5× 44 1.8k
Birgitte Smith‐Sørensen Norway 17 1.4k 1.6× 1.4k 1.6× 289 0.9× 674 2.5× 156 0.7× 25 2.4k
Anne Estreicher Switzerland 15 537 0.6× 756 0.9× 234 0.7× 693 2.5× 286 1.2× 24 1.6k
Kenta Kawasaki Japan 14 1.1k 1.2× 516 0.6× 101 0.3× 413 1.5× 156 0.7× 37 1.6k

Countries citing papers authored by Gail Eckhardt

Since Specialization
Citations

This map shows the geographic impact of Gail Eckhardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gail Eckhardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gail Eckhardt more than expected).

Fields of papers citing papers by Gail Eckhardt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gail Eckhardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gail Eckhardt. The network helps show where Gail Eckhardt may publish in the future.

Co-authorship network of co-authors of Gail Eckhardt

This figure shows the co-authorship network connecting the top 25 collaborators of Gail Eckhardt. A scholar is included among the top collaborators of Gail Eckhardt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gail Eckhardt. Gail Eckhardt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dj, Kim, Bert Ely, Aik Choon Tan, et al.. (2018). Abstract P5-21-16: Preclinical studies of RX-5902, a beta-catenin modulator in triple negative breast cancer. Cancer Research. 78(4_Supplement). P5–21. 1 indexed citations
2.
Ferrarotto, Renata, Gail Eckhardt, Akash Patnaik, et al.. (2018). A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Annals of Oncology. 29(7). 1561–1568. 101 indexed citations
3.
4.
Capasso, Anna, Todd M. Pitts, S. Lindsey Davis, et al.. (2017). Abstract 1662: Development and validation of humanized mice models implanted with patient derived colorectal cancer xenografts. Cancer Research. 77(13_Supplement). 1662–1662. 1 indexed citations
5.
6.
Oweida, Ayman, Shilpa Bhatia, Todd M. Pitts, et al.. (2016). Ephrin‐B2 overexpression predicts for poor prognosis and response to therapy in solid tumors. Molecular Carcinogenesis. 56(3). 1189–1196. 33 indexed citations
7.
Song, Eun‐Kee, Wells A. Messersmith, Stacey M. Bagby, et al.. (2014). Potent antitumor activity of cabozantinib, a c‐MET and VEGFR2 inhibitor, in a colorectal cancer patient‐derived tumor explant model. International Journal of Cancer. 136(8). 1967–1975. 49 indexed citations
8.
Jimeno, Antonio, Daniel W. Bowles, Dara L. Aisner, et al.. (2013). Abstract LB-198: Phase I and molecular correlates study of oral rigosertib in patients with refractory metastatic head and neck cancer and advanced solid tumors.. Cancer Research. 73(8_Supplement). LB–198. 2 indexed citations
9.
Infante, Jeffrey R., Leslie A. Fecher, Gerald S. Falchook, et al.. (2012). Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. The Lancet Oncology. 13(8). 773–781. 424 indexed citations breakdown →
10.
Nallapareddy, Sujatha, Stephen Leong, D. Ross Camidge, et al.. (2009). Abstract B238: A phase 1 study of belinostat (PXD101) in combination with bortezomib in patients with advanced solid tumors or lymphoma. Molecular Cancer Therapeutics. 8(12_Supplement). B238–B238. 1 indexed citations
11.
Philip, Philip A., Margaret Mooney, Deborah Jaffe, et al.. (2009). Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment. Journal of Clinical Oncology. 27(33). 5660–5669. 172 indexed citations
12.
Xu, Rui‐Hua, C. Y. Huang, Daniel Branstetter, et al.. (2007). Application of pharmacodynamic assays in a phase Ia trial of Apo2L/TRAIL in patients with advanced tumors. Journal of Clinical Oncology. 25(18_suppl). 3535–3535. 18 indexed citations
13.
Herbst, Roy S., Scot Ebbinghaus, Michael S. Gordon, et al.. (2006). A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. Journal of Clinical Oncology. 24(18_suppl). 3013–3013. 77 indexed citations
14.
Bianco, Cataldo, Elisa Giovannetti, Fortunato Ciardiello, et al.. (2006). Synergistic Antitumor Activity of ZD6474, An Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, with Gemcitabine and Ionizing Radiation against Pancreatic Cancer. Clinical Cancer Research. 12(23). 7099–7107. 46 indexed citations
15.
Leong, Stephen, D. Ross Camidge, Gail Eckhardt, et al.. (2006). A phase I dose-escalation and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced cancer. Journal of Clinical Oncology. 24(18_suppl). 2048–2048. 9 indexed citations
16.
Zhou, Honghui, Henry Lau, Elisabeth G.E. de Vries, et al.. (2000). Population Pharmacokinetics/Toxicodynamics (PK/TD) Relationship of SAM486A in Phase I Studies in Patients with Advanced Cancers. The Journal of Clinical Pharmacology. 40(3). 275–283. 25 indexed citations
17.
Ganly, Ian, David H. Kirn, Gail Eckhardt, et al.. (2000). A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.. PubMed. 6(3). 798–806. 348 indexed citations
18.
Izbicka, Elżbieta, R. A. Lawrence, Éric Raymond, et al.. (1998). In vitro antitumor activity of the novel marine agent, Ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Annals of Oncology. 9(9). 981–987. 122 indexed citations
19.
Dorr, F. Andrew, et al.. (1997). ISIS 3521/CGP 64128A- antisense to protein kinase C-alpha. European Journal of Cancer. 33. S52–S52.
20.
Eckhardt, Gail, et al.. (1984). [HDL and LDL cholesterol changes in psychological stress in relation to stress experience].. PubMed. 39(12). 273–7. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark L. Levitt Breakdown of academic impact, for papers by Ying C. Henderson Breakdown of academic impact, for papers by Jack A. Roth Breakdown of academic impact, for papers by Dahmane Oukrif Breakdown of academic impact, for papers by Richard K. Rosenberg Breakdown of academic impact, for papers by Charanjit Sandhu Breakdown of academic impact, for papers by Adam D. Steg Breakdown of academic impact, for papers by Birgitte Smith‐Sørensen Breakdown of academic impact, for papers by Anne Estreicher Breakdown of academic impact, for papers by Kenta Kawasaki
Rankless by CCL
2026